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Background—Atherosclerosis, the precursor to coronary heart disease and stroke, is
characterized by accumulation of fatty cells in the arterial intimal-medial layers. Common carotid
intima media thickness (cIMT) and plaque are subclinical atherosclerosis measures that predict
cardiovascular disease events. Previously, genome-wide association studies demonstrated
evidence for association with cIMT (SLC17A4) and plaque (PIK3CG).
Methods and Results—We sequenced 120kb around SLC17A4 (6p22.2) and 251kb around
PIK3CG (7q22.3) among 3,669 European ancestry participants from the Atherosclerosis Risk in
Communities Study, Cardiovascular Health Study, and Framingham Heart Study in the Cohorts
for Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium. Primary
analyses focused on 438 common variants (minor allele frequency [MAF] ≥ 1%), which were
independently meta-analyzed. A 3’ UTR CCDC71L variant (rs2286149), upstream from PIK3CG,
was the most significant finding in cIMT analyses (p= 0.00033) and plaque (p=0.0004). A
SLC17A4 intronic variant was also associated with cIMT (p=0.008). Both were in low LD with the
GWAS SNPs. Gene-based tests including T1 count and SKAT for rare variants (MAF < 1%), did
not yield statistically significant associations. However, we observed nominal associations for rare
variants in the CCDC71L and SLC17A3 with cIMT and of the entire 7q22 region with plaque
(p=0.05).
Conclusions—Common and rare variants in the PIK3CG and SLC17A4 regions demonstrated
modest association with subclinical atherosclerosis traits. While not conclusive, these findings
may help to understand the genetic architecture of regions previously implicated by GWAS and
identify variants within these regions for further investigation in larger samples.
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Atherosclerosis, a precursor to clinical coronary artery disease and some strokes, is
characterized by an accumulation of fatty and inflammatory cells and fibrosis in the intimal-
medial layers of the arteries. Common carotid intima media thickness (cIMT) and plaque,
reflecting a thickening of the carotid artery wall or the presence of large irregular arterial
wall deposits, respectively, are established measures of subclinical atherosclerotic disease
that can be detected non-invasively and with reasonable precision in population samples
using high resolution ultrasound techniques. Multiple independent studies have established
consistent association of abnormal carotid phenotypes with coronary events and stroke in
prospective studies of young, middle-aged, and older adults,1, 2 and recent consensus
prevention guidelines cite cIMT as a potentially useful measure for prediction of these
outcomes.3
We have previously identified two regions that demonstrated evidence for association with
cIMT (SLC17A4) and carotid plaque (PIK3CG) in a large-scale genome-wide association
meta-analysis conducted among over 40,000 participants from population-based studies of
European-ancestry adults.4 Recent studies have shown that targeted genome sequencing can
identify a significant excess burden of functional variants underlying GWAS signals. 5 To
identify the causal variants accounting for these signals, we performed a targeted sequencing
of these loci using next generation technology. The first region is a 120kb window on
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chromosome 6p22.2 including the SLC17A4, SLC17A1, and SLC17A3 genes that showed
suggestive evidence for association with common cIMT in the GWAS (rs4712972,
MAF=0.12, β=0.0099, p = 7.8 × 10−8).4 The second targeted region is a 251kb stretch of
chromosome 7q22.3 including the PIK3CG gene that was significantly associated with
increased risk of carotid plaque in the GWAS (rs17398575, MAF=0.25, OR=1.18,
p=2×10−12). 4 In addition to association with plaque, this region was also selected for
sequencing on the basis of its association in recent GWAS with both platelet volume 6 and
aggregation 7 as well as pulse pressure. 8.
Rather than identifying new susceptibility loci, our aim was to better characterize the
landscape of common and rare variation in these previously associated regions and to
determine whether novel or low frequency variation therein was associated with cIMT and
carotid plaque. Such fine-mapping across the full spectrum of allele frequencies may help to
explain previous genome-wide associations and provide new information on potential
mechanisms of atherosclerosis that could contribute to subclinical cardiovascular disease.
Methods
Participating studies
Our analyses were performed within the Cohorts for Heart and Aging Research in Genomic
Epidemiology (CHARGE) Consortium’s9 Targeted Sequencing Study, which included
3,688 European ancestry participants from the Atherosclerosis Risk in Communities Study10
(ARIC), the Cardiovascular Health Study11 (CHS), and the Framingham Heart Study12, 13
(FHS). This sample included a sex-stratified subset of approximately 200 individuals that
were selected for elevated measures of age-adjusted cIMT (see Supplementary Note). The
remainder of the participants in this study was selected as part of a large random sample or
for extreme values of 13 other cardiovascular related phenotypes. Institutional review boards
at all participating centers approved the study, and participants gave informed consent.
Additional information about the design of these studies is included in the Online Data
Supplement.
Carotid artery phenotypes
Each study evaluated the carotid arteries using high-resolution B-mode ultrasonography,
using previously described reading protocols to define phenotypes, as per our previous
report.4 For these analyses, we used data from the baseline examination or the first
examination in which carotid ultrasonography was obtained. Our primary analysis
concerned the common carotid artery using the intima media thickness, typically
summarized as the mean of the maximum of several carotid measurements. For most
studies, this was an average of multiple measurements from both the left and right arteries.
All studies measured the far wall, and several also included the near wall. We also examined
the atherosclerotic thickening of the carotid artery wall, defined in two studies by the
presence of plaque (CHS, ARIC) or the proxy measure of luminal stenosis greater than 25%
(FHS). Specific details for each study’s ultrasound, reading, and plaque definition protocols
are provided in the Online Data Supplement.
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The methods of the CHARGE Targeted Sequencing Study have been described fully in a
separate manuscript (Lin H, Wang M, Brody JA, Bis JC, Dupuis J, Lumley T, et al.,
submitted to Circ Cardiovasc Genet along with this manuscript). Briefly, the Study
sequenced a total of 77 target regions that harbor genetic variants associated with 14
phenotypes implicated by GWAS within the CHARGE Consortium. Two of the selected
genes were particularly relevant to subclinical atherosclerosis. First, the Subclinical
Phenotype Group used the University of California at Santa Cruz (UCSC) Genome Browser
to select target sequence upstream and downstream of the SLC17A4/3/1 genes. Secondly, the
Pleiotropy Phenotype Group selected the PIK3CG region with the aim of capturing both the
gene as well as the upstream CCDC71L gene and other untranslated regions that harbored
SNPs identified in several GWAS.
Approximately 2Mb of target regions were captured by a customized NimbleGen Capture
array and sequenced using the ABI SOLiD V4.0 platform. The raw short reads were aligned
to the reference human genome (NCBI Genome Build 36, hg18) by BFAST.14 Samtools15
was used to pile up aligned reads and call variants with quality filters. The resulting data was
then subjected to quality control procedures. Variants were categorized as known or novel
by comparison with the dbSNP database and the 1000 Genomes Project. The functional
impact of identified variants on the encoded proteins was predicted by the ANNOVAR
software package.16
Statistical analysis within studies
Each study independently implemented a predefined and standardized analysis plan, as
described below.
For the continuous measures of cIMT, we evaluated cross-sectional associations of natural
log of cIMT [ln(cIMT)] and genetic variation using linear regression models (or linear
mixed effects models in FHS to account for family relatedness). For the dichotomous
outcome of plaque, each study used logistic regression models (or general estimating
equations clustering on family, to account for familial correlations). In our primary analyses,
all studies were adjusted for age, sex, and principal components to account for population
substructure (as needed). Some studies made additional adjustments including study site
(CHS, ARIC) or familial structure (FHS). For cIMT, we expressed the association of each
SNP and ln(cIMT) as the regression slope (β), its standard error [SE(β)] and a corresponding
p-value. For the presence of plaque, we calculated a log odds ratio (OR), 95% confidence
interval, and p-value. In this case, the OR represents the increase or decrease in the odds of
plaque for each additional copy of the variant ’s coded allele. Each study repeated these
analyses weighted by each participant’s sampling probability to obtain valid estimates of
effect size. (Lumley T, Dupuis J, Rice KM, Barbalic M, Bis JC, Cupples LA, et al. http://
stattech.wordpress.fos.auckland.ac.nz/files/2012/05/design-paper.pdf)
We applied two methods of analysis within each region for each of these traits. For each
variant with a MAF ≥ 1% in the combined population, each study fit additive genetic
models, regressing trait on genotype dosage (0 to 2 copies of the variant allele). For rare
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variants, our primary analyses aggregated rare alleles, i.e., those with MAF < 1% into a T1
count statistic, which was defined as the number of variant sites in the target at which a
person has at least one rare allele with MAF < 1%. In secondary rare variant analyses of our
target regions, we used two approaches: (1) First, we used a Madsen-Browning (MB) type
test, which aggregates all variants with MAF< 1% in a genomic region, weighting each
variant by a function of its MAF.17 (2) Second, to explore the possibility that rare variants
within a gene did not have the same direction or magnitude of association, we implemented
the Sequence Kernel Association Test (SKAT)18, which approximates the score test that
would be obtained fitting a model that includes all the variants.19
We then conducted a meta-analysis of regression estimates and standard errors using an
inverse-variance weighting approach, implemented in METAL20 or, for SKAT, using
customized R scripts. (Lumley T, Brody J, Dupuis J, Cupples LA http://
stattech.wordpress.fos.auckland.ac.nz/files/2012/11/skat-meta-paper.pdf). For the meta-
analysis of common variants we excluded SNPs observed in only one study and discarded
results with heterogeneity p-values less than 1× 10-5. As described above, meta-analysis of
unweighted regression coefficients was used to determine significance and meta-analysis of
weighted regression coefficients were used to estimate effect size for single variants.
Our primary hypotheses focused on descriptive analyses of genetic sequence variants in the
SLC17A4 and PIK3CG regions. Given the prior evidence for these two regions, we used a p-
value threshold of p<0.01 to identify common variants of potential interest. However, we
also performed exploratory analyses across the remaining 75 sequenced targets. Given the
hypothesis-free nature of these analyses, we considered only regions satisfying a more
stringent “target-wide significance” threshold (p<1×10-5 for common SNPs: 0.05/4800
common variants across the entire sequencing project; or p<0.00067, 0.05/75 targets for
burden tests).
Regulatory function of SNPs
We used HaploReg21 to evaluate regulatory function for variants identified in the study
(www.broadinstitute.org/mammals/haploreg/haploreg.php). HaploReg is a tool for exploring
annotations of the noncoding genome at variants on haplotype blocks that uses LD
information from the 1000 Genomes Project. Linked SNPs and small indels are visualized
for conservation across mammals, and their effect on regulatory motifs from the ENCODE
project, and their predicted chromatin state in nine cell types: embryonic stem cells (H1 ES);
erythrocytic leukemia cells (K562); B-lymphoblastoid cells (GM12878); hepatocellular
carcinoma cells (HepG2); umbilical vein endothelial cells (HUVEC); skeletal muscle
myoblasts (HSMM); normal lung fibroblasts (NHLF); normal epidermal keratinocytes
(NHEK); and mammary epithelial cells (HMEC).
Results
Our analysis included 3,669 participants who had carotid ultrasound measures and
successful targeted sequencing; characteristics of these participants are shown in Table 1
according to whether they were sampled into the study for extreme values of cIMT, extreme
values of another cardiovascular phenotype, or as part of the Cohort Random Sample. As
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expected, participants sampled from the cIMT extremes had greater cIMT and were more
likely to have plaque, while those sampled for other cardiovascular traits resembled the
Cohort Random Sample in terms of these subclinical atherosclerosis phenotypes.
The overall CHARGE Targeted Sequencing Study identified 52,736 variants across all
successfully sequenced participants – most were rare variants (only 4,800 had a minor allele
frequency greater than 1%). Our primary analyses focused on 3,767 variants in two genomic
regions – 6p22 (110 common, 656 rare) and 7q22 (328 common, 2,673 rare) – that had
previously associated with subclinical atherosclerosis traits. A summary of the genomic
annotation for these variants is shown in Supplementary Table 1.
Common Variants Results
Figure 1 displays the regional plots with results of the meta-analysis for common variants in
the 6p22 and 7q22 regions; Supplementary Tables 2A and 2B present the results for
individual common variants with p-values less than 0.01 for either cIMT or plaque.
Supplementary Figures 1A and B shows the Manhattan plot of all common variant
associations across the 77 target regions for cIMT and plaque, respectively.
For the 6p22 region spanning SLC17A4, the strongest finding was for a newly-discovered
intronic variant with cIMT (rs141877104, MAF=0.015, p=0.008). This variant was in low
LD (r2=0.003) with the common GWAS signal SNP, rs4712972, which was only nominally
associated with cIMT in our sequenced subsample (p=0.04). In the analysis of plaque
another intronic SLC17A4 variant (rs76788698, MAF=0.021) was modestly associated with
the presence of plaque (p=0.04) and was in low LD with rs4712972 (r2=0.1). While the
correlation-based estimates of LD for these SNPs and the GWAS signal variant were low,
there is little evidence of recombination in this region (D’>0.9, Figure 1) suggesting that the
signal GWAS SNP could be tagging underlying rarer variant associations. Although neither
of these variants were present in the Phase II HapMap CEU panel, they have been reported
in the latest version of the 1000 Genomes data.
In the chromosome 7q22 region, we observed the smallest p-value for a common variant
rs2286149 (MAF=0.12) for both cIMT (β= 0.018, p-value= 0.0003) and plaque (O.R.=1.4;
p-value=0.0003). This variant falls in the 3’ UTR of CCDC71L, upstream from the targeted
PIK3CG gene. The plaque GWAS signal variant (rs17398575) is located between these two
genes, but was not significantly associated with the presence of plaque (p=0.5) in this subset
sample of the large GWAS and is in low LD (r2 = 0.002, D’= 0.11) with rs2286149 in our
sequenced sample.
Functional follow-up of the common variants
Applying HaploReg, we evaluated regulatory function for variants shown in Supplementary
Table 2A. We found that rs2190093 affects the HP1-site-factor motif, which is necessary to
generate a liver-specific promoter, and is in perfect LD with rs2286149, itself strongly
associated with both cIMT (p=0.0007) and plaque (p=0.0004) in this sequencing study. This
common variant is located in the 3’UTR region of gene CCDC71L, upstream from the
targeted PIK3CG gene. The implicated promoter binds to a liver-specific transcription
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factor, hepatocyte nuclear factor 1 (HNF1A) which is also known as HNF1 and
HNF-1alpha. HNF1A is known to regulate the expression of several liver-specific genes.
We queried TRANSFAC (http://www.biobase-international.com/product/transcription-
factor-binding-sites), a unique knowledge-base of published data on eukaryotic transcription
factors, their experimentally-proven binding sites, and regulated genes, we found that target
genes of HNF1A include those related to coagulation, lipids, C-reactive protein,
inflammation and toxic stress (Supplementary Table 3).
Rare variants
We conducted gene-based rare variant analyses for each of the two chromosomal regions as
well as for the five sub-regions within these loci defined by the UCSC gene boundaries
(Table 2). We did not observe any statistically significant findings for association between
cIMT or plaque with any of these gene-based tests, although we noted suggestive
associations of the SLC17A3 sub-region with cIMT (MB p=0.04), the CCDC71L sub-region
with cIMT (T1 p=0.05; SKAT p=0.05) and the overall 7q22 region with plaque (T1,
p=0.05). Further, limiting the SKAT tests to a set of potentially functional variants (non-
synonymous, splice sites, or non-coding SNPs with some evidence of regulatory function
defined by RegulomeDB.org score < 6) with MAF < 0.05 did not improve the evidence for
association for these genes.
For the remaining 75 regions identified by the CHARGE Targeted Sequencing Study, no
common variants or T1 rare variant burdens showed statistically significant associations
between cIMT or plaque.
Discussion
In the meta-analysis of association between common sequence variants and subclinical
atherosclerosis traits, a variant in the 3’ UTR of CCDC71L, rs2286149, showed the smallest
p-value in both analyses of cIMT and plaque (p-value=0.0003). This variant is located
upstream of the targeted PIK3CG gene. For the 6p22 region, the strongest finding was for
anintronic SLC17A4 variant (rs141877104) with cIMT (p=0.008), which provides modest
evidence toward localizing the broad GWAS peak to one member of the three-gene cluster.
The 7q22 region targeted for sequencing in this study contains two genes, PIK3CG and
CCDC71L. In addition to the association with plaque in our previous GWAS, variants in this
region are also strongly associated with mean platelet volume 22, 23. In particular, variants in
the CCDC71L, (coiled-coil domain containing 71-like) have been previously associated with
expression of the PIK3CG gene as a platelet eQTL. 6 PIK3CG encodes one of the pi3/pi4-
kinase family of proteins, important modulators of extracellular signals, including those
elicited by E-cadherin-mediated cell-cell adhesion, which plays an important role of
endothelin in maintenance of the structural and functional integrity of epithelia. In our
sequencing study a common variant in the CCDC71L was strongly associated with both
cIMT and plaque. This variant, rs2286149, shows only modest evidence of regulatory
function as it alters the Zfp105 regulatory motifs; is in an active promoter for chromatin
states in several cell types (HMEC, Uuvec, K562, and NHLF), polycomb repression in
HepG2, and falls within a DNAseI hypersensitivity peak in hepatocytes. In the 3’UTR
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region of gene CCDC71L, another common variant, rs2190093, is in perfect LD with the top
associated SNP rs2286149 (r2=1.0), and is also found to be strongly associated with both
cIMT and plaque in this sequencing study. rs2190093 affects the binding site of a liver-
specific transcription factor, hepatocyte nuclear factor 1 (HNF1A). Reported targets of
HNF1A include CRP, APOB, APOA2 and coagulation factors including F2, F8, and β-
fibrinogen (FGB).2425. ITGA2B, platelet glycoprotein IIb, is also a target of HNF1A.
Although rs2190093 is in 3’UTR of CCDC71L, it is also located in 5’ upstream regulatory
region of PIK3CG, which harbors variants associated with both carotid phenotypes as well
as platelet number and volume 26and aggregation 27in large GWAS. These results generate
the hypothesis that PIK3CG may be an HNF1A target expressed in platelets. Rare variant
tests in the CCDC71L gene showed borderline evidence for association with cIMT and rare
variant tests across the entire 7q22 region showed borderline association with plaque.
The chromosome 6p22 region, targeted in this study on the basis of a suggestive association
of rs4712972 with common carotid IMT in our previous GWAS, includes SLC17A4,
SLC17A1, and SLC17A3; the products of these genes are involved in renal phosphate
homeostasis. Serum phosphate has been associated with subclinical atherosclerosis: 2829.
SLC17A1 is located in the proximal tubules in the kidney and is responsible for renal
excretion of Ph; SLC17A4 is located in the intestine. In addition, two GWAS have
associated this region with uric acid levels (SLC17A1 30, SLC17A3 31). The association peak
was broad in our GWAS that used imputation to the Phase II HapMap CEU reference panel,
and the strongest associations in this sequenced subset were for intronic variants in the
SLC17A4 gene that were not present in the HapMap. There is little evidence for regulatory
potential for these two variants, though one (rs112544908), which modifies a Pax-3 binding
site, was associated with cIMT (p=0.009) and modestly, with higher risk of plaque (p=0.09).
The GWAS that originally identified these loci as associated with subclinical atherosclerosis
traits included a much larger sample size and relied on imputation to the Phase II HapMap
reference panel. In the current targeted sequencing study, conducted among a subset of
participants from three cohorts that comprised the large-scale discovery effort, neither of the
prior GWAS top SNPs that identified these loci as targets was strongly associated with
either of the subclinical traits. This effort was primarily a comprehensive, descriptive
analysis targeted at better characterize variation in regions identified by GWAS; as such, we
reported results for variants with p<0.01. However, we acknowledge that few of the findings
we have described would satisfy a conservative Bonferroni correction for the total number
of tests (p=0.0001, 0.05/~450 common variants) or for one expected false positive
accounting for the correlation between the variants (p=0.007, or 1/~140 effectively
independent tests). In part, this lack of association could reflect diminished power,
particularly for the dichotomous analyses, of this smaller sample size. For instance, our
power in the targeted sequencing analysis to discover common variants was excellent (99%)
for a single SNP that explained 1% of the overall variance in the trait, but was only
moderate (69%) for a variant that explained 0.5% of the trait variance. Nevertheless, these
findings from fine-mapping may better localize associations. For instance, the original
GWAS signal for plaque fell in an apparent recombination region between PIK3CG and
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CCDC71L. The sequencing data showed no evidence for association of this GWAS variant
with plaque, instead exposing CCDC71L, as the potentially relevant locus.
In summary, sequencing of the PIK3CG and SLC17A4 regions within a limited number of
participants from three CHARGE cohorts demonstrated evidence of association between
plaque and the PIK3CG region for both common and rare variants. While not conclusive,
these findings may help to better understand the genetic architecture of two regions
previously implicated in subclinical atherosclerosis.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Regional association plots for common sequence variants and subclinical atherosclerosis
phenotypes. Associations of sequenced common variants for the 6p22 (SLC17A4, a & c) and
7q22 (PIK3CG, b & d) regions and subclinical atherosclerosis phenotypes are plotted
according to their chromosomal position on the x-axis (NCBI Genome Build 37, 2009). The
y-axis provided the -log10 P value of each variant’s association with cIMT (a & b) or plaque
(b & d). Variants are colored based on the linkage disequilibrium (r2) to the most significant
SNP (red diamond) in each region. Genes are indicated by green arrows and the
recombination rate is shown with blue lines.
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